Stabilized plasmid-lipid particles: construction and characterization. - Wikidata - wikimedia - TriplyDB

Stabilized plasmid-lipid particles: construction and characterization.

Stabilized plasmid-lipid particles: construction and characterization.

http://www.wikidata.org/entity/Q40937486

about

Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics Ultrasound-enhanced microfluidic synthesis of liposomes.Cationic lipid nanodisks as an siRNA delivery vehicle Surface functionalized cationic lipid-DNA complexes for gene delivery: PEGylated lamellar complexes exhibit distinct DNA-DNA interaction regimes Cationic lipid-mediated transfection in vitro and in vivo (review).Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.Combinatorial library strategies for synthesis of cationic lipid-like nanoparticles and their potential medical applications.Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer.Addition of ascorbic acid to the extracellular environment activates lipoplexes of a ferrocenyl lipid and promotes cell transfection Liposome-encapsulated polyethylenimine/oligonucleotide polyplexes prepared by reverse-phase evaporation technique.Cationic lipid-DNA complexes for non-viral gene therapy: relating supramolecular structures to cellular pathways.Cell-specific targeting of lipid-based carriers for ODN and DNA.Parallel lipoplex folding pathways revealed using magnetic tweezers A covalently stabilized lipid-polycation-DNA (sLPD) vector for antisense oligonucleotide delivery Sheddable coatings for long-circulating nanoparticles.Liposomal nanomedicines.Chemical activation of lipoplexes formed from DNA and a redox-active, ferrocene-containing cationic lipid.Electron spin resonance spectroscopy in drug delivery.Cationic liposome-nucleic acid complexes for gene delivery and silencing: pathways and mechanisms for plasmid DNA and siRNA.Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles.Challenges in the pharmaceutical development of lipid-based short interfering ribonucleic acid therapeutics.Nucleic-acid based gene therapeutics: delivery challenges and modular design of nonviral gene carriers and expression cassettes to overcome intracellular barriers for sustained targeted expression.Delivery of RNAi therapeutics: work in progress.Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology.Delivering the promise of small ncRNA therapeutics.Interference of poly(ethylene glycol)-lipid analogues with cationic-lipid-mediated delivery of oligonucleotides; role of lipid exchangeability and non-lamellar transitions.Self-assembling micelle-like nanoparticles based on phospholipid-polyethyleneimine conjugates for systemic gene delivery.Mastering Dendrimer Self-Assembly for Efficient siRNA Delivery: From Conceptual Design to In Vivo Efficient Gene Silencing.Co-delivery of doxorubicin and PEGylated C16-ceramide by nanoliposomes for enhanced therapy against multidrug resistance.Preparation, characterization, and efficient transfection of cationic liposomes and nanomagnetic cationic liposomes Folate-targeted liposome encapsulating chitosan/oligonucleotide polyplexes for tumor targeting.Lipid nanoparticle delivery systems for siRNA-based therapeutics.Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.The effect of cholesterol domains on PEGylated liposomal gene delivery in vitro Development of lipidoid-siRNA formulations for systemic delivery to the liver.Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.Targeting of stabilized plasmid lipid particles to hepatocytes in vivo by means of coupled lactoferrin.Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA.Relationship between the physical shape and the efficiency of oligomeric chitosan as a gene delivery system in vitro and in vivo.Stabilized plasmid-lipid particles for systemic gene therapy.

P2860

Q24616751-6CF694AB-85B0-48C5-9A67-F778414D7D82 Q30448520-60074FD2-903B-4D38-AA11-C1F248AC6895 Q33745473-4B4EAD25-828F-46C7-87F6-83BEA6F14DCC Q34184671-A1EB4EFF-4050-4160-BF8A-4882400F6591 Q34313548-577C463B-2D18-43D7-BC55-3BD5991E9D5E Q34436572-F046AF24-F861-4E3C-BF90-4547F11AC25D Q35568750-40857B88-097A-4D8D-AA9A-1EA76D14B6EB Q35630481-AC0D22BF-FB47-4A77-A1BD-DCC9C00F0A7B Q35675391-C37A9630-973F-48D5-906C-E1A75736BFA0 Q35999058-DC0DF1F3-8D95-42BB-BAA9-01A746DE189A Q36040801-64BDF414-24BF-4E76-8C01-C716BC0E2779 Q36272601-E83706F5-34BA-4E79-8CA9-B4B7C229ABD2 Q36334727-98488612-6D67-4C24-866C-4035C8AAFCEF Q36691274-2D7E5246-3CFA-4C5D-96C5-8A9B9603DDA1 Q36841604-F4D882F8-3B2A-4C2F-875C-919718E99738 Q37039021-5C2F86DA-EEC1-46CF-BAF7-8587342BDB18 Q37105021-5BE78FFA-63AF-40F3-B974-06EDCBEA4563 Q37352715-88086860-80A0-4B6C-BD66-61E562A83C20 Q37403081-0FEA523F-F656-4599-8942-A5A111B66A06 Q37588032-7B135522-F656-409D-8F10-9EC2D18B94B2 Q37976494-C111EC2D-0AE2-4C0B-8176-54ECE880C473 Q37981217-2733005A-3681-4E5D-89E0-004857162328 Q38160246-29A8F795-30F8-47CB-B427-4205265F42E8 Q38162098-99664908-875B-49D6-89BE-5D6426034017 Q38226666-FB475AE6-E05F-4134-9EC0-6140BC211879 Q38288939-D2B9A087-1C45-47DC-83F0-BCF3E4976E62 Q38598120-437AC581-1DDC-464A-90B0-74F5639E4E8B Q38860419-B0343607-9915-499A-AE72-03B7C3CB742A Q38862896-74455914-E113-477B-A1A8-C27D1B2EC5C4 Q38885218-B75768AF-1808-45A0-B670-32EABF6D7969 Q38993006-B3B6B4C8-E464-4EDA-B296-5F338D906828 Q39027758-A3580749-3E56-499F-9649-0F2564573146 Q39323667-D2D94A18-CAEA-491C-8DDB-336883D70748 Q39377390-8CB6D648-EE78-418D-BE27-B6FCDBFB28AE Q39506235-CAB88F69-F72A-485F-BE7F-7E33888B384F Q39913293-0D419C79-2572-47F8-A871-4008F996155C Q40060375-982D38A8-8490-4EB4-98C9-810BE41F61A9 Q40159983-43B3FA8F-2454-4D2C-AD15-C494EA061EEA Q40675811-D86DD140-9F9A-412F-96C8-B26ECC81BE2E Q41631274-8291C3B7-9348-4371-99A2-BE7D5C1EBA7E

P2860

Stabilized plasmid-lipid particles: construction and characterization.

http://www.wikidata.org/entity/Q40937486

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

1999年论文

@zh

1999年论文

@zh-cn

name

Stabilized plasmid-lipid particles: construction and characterization.

@en

type

label

Stabilized plasmid-lipid particles: construction and characterization.

@en

prefLabel

Stabilized plasmid-lipid particles: construction and characterization.

@en

P1433

Q40937486-15F35350-7126-4BD1-B8E9-7169477EBDE6

P1476

Q40937486-EBA6F810-35C6-4ED1-B30A-D0161632A57D

P2093

Q40937486-30ECCA03-527D-495D-A1EB-C569DBD9D28A

Q40937486-42744B7A-DBB8-4B28-AC19-E1A59E184EA6

Q40937486-69E8D065-0094-4358-89AB-AF4615FCF7CC

Q40937486-852FFA8F-3486-4F7B-9BAE-6A2F9ABC7A29

Q40937486-96439DBF-D29C-4820-AF49-8339E81920AC

Q40937486-9E93435F-8CAD-4DFA-8277-61EFA50CAD9C

Q40937486-DA6BE988-875B-4A55-BB28-A957DDA3BC39

Q40937486-ED834766-3231-4536-A560-24E32ABCDE94

Q40937486-F8E6ECDB-C9FB-444B-8D84-D4376A761904

P2860

Q40937486-0FD356F0-62EE-4FB7-84FD-8F5F2F894654

Q40937486-10F550A5-503B-4FAF-9C36-9A3043BC60FA

Q40937486-2C140FDB-8B03-42BA-B12D-11D024A62C04

Q40937486-2E7C286B-DDFB-485E-81E0-DF53F20D10A0

Q40937486-2EE54202-A369-4BE3-B06E-16E271AAB2B7

Q40937486-3353B52B-C403-4F95-8600-4CB2EB449E10

Q40937486-45B05346-A3A4-41BD-ABDB-B59B4CF3B7F7

Q40937486-471BD4D8-0DFE-48E2-9633-9C379CEA09C6

Q40937486-540B90E4-DE8B-44A8-A529-E31DC0F4AE17

Q40937486-602F5705-5962-4084-B84D-27B7429FE875

P2888

Q40937486-05278EE6-36D6-45AF-8BED-1E2A755BEF80

P304

Q40937486-4D8BF74C-B9F5-4DB0-AEC8-24EA10BFC1C1

P31

Q40937486-33C567C2-7C77-4E1A-BEE7-249E60EA1CB6

P356

Q40937486-57418ED8-DDEE-4982-AD04-DC2ED68AC734

P433

Q40937486-975D9183-B1E4-477E-9968-97B1C41F737E

P478

Q40937486-D65E67D4-24CD-4145-94BD-93270595FB5B

P577

Q40937486-480EBE5D-D011-47A5-BF5A-0D5A6800C3DB

P5875

Q40937486-AFAEEE7C-AE93-471F-B383-33691D7E520D

P6179

Q40937486-33088C7C-8A4D-4A56-8241-666894BD6795

P698

Q40937486-26402BC0-A2EB-4213-8940-2D08A9AAC4F5

P356

P1433

P1476

Stabilized plasmid-lipid particles: construction and characterization.

@en

P2093

Cullis PR

http://www.w3.org/2001/XMLSchema#string

Graham RW

http://www.w3.org/2001/XMLSchema#string

Hope MJ

http://www.w3.org/2001/XMLSchema#string

MacLachlan I

http://www.w3.org/2001/XMLSchema#string

Ossanlou M

http://www.w3.org/2001/XMLSchema#string

Palmer L

http://www.w3.org/2001/XMLSchema#string

Scherrer P

http://www.w3.org/2001/XMLSchema#string

Wheeler JJ

http://www.w3.org/2001/XMLSchema#string

Zhang YP

http://www.w3.org/2001/XMLSchema#string

P2860

A rapid alkaline extraction procedure for screening recombinant plasmid DNA

Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors

Systemic gene therapy: biodistribution and long-term expression of a transgene in mice.

pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse.

Basic protein enhances the incorporation of DNA into lipid vesicles: model for the formation of primordial cells

Intracellular fate of liposome-encapsulated DNA in mouse liver. Analysis using electron microscope autoradiography and subcellular fractionation.

Entrapment of a bacterial plasmid in phospholipid vesicles: potential for gene transfer.

Targeted and nontargeted liposomes for in vivo transfer to rat liver cells of a plasmid containing the preproinsulin I gene.

The polymorphic phase behaviour of phosphatidylethanolamines of natural and synthetic origin. A 31P NMR study.

Vesicle-micelle transition of phosphatidylcholine and octyl glucoside elucidated by cryo-transmission electron microscopy.

P2888

P304

271-281

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.GT.3300821

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

1999-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12864889

http://www.w3.org/2001/XMLSchema#string

P6179

1041443639

http://www.w3.org/2001/XMLSchema#string

P698

10435112

http://www.w3.org/2001/XMLSchema#string